Shukra Pharmaceuticals Ltd.
64.46
INR
+1.93
(+3.09%)
Shukra Pharmaceuticals Ltd.
NSE:SHUKRAPHAR
(National Stock Exchange of India)
Recent
price
64.46
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Shukra Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical products. Its core product portfolio includes oral solid dosage forms such as tablets and capsules, small volume parenteral forms including liquid injection vials and ampoules, and a comprehensive range of therapeutic categories including macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedatives and tranquillizers, anti-depressants, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesics, muscle relaxants, anti-tuberculosis, vitamins, anti-allergics, corticosteroids, hyper and hypoglycemic drugs, penicillin, and cephalosporin antibiotics. The company manufactures approximately 40 million ampoules and 50 million vials, along with 720 million tablets and 90 million capsules annually. It operates through a global outreach primarily in the Commonwealth of Independent States (CIS), Africa, and Southeast Asian countries. Founded in 1993 and headquartered in Ahmedabad, Gujarat, India, Shukra Pharmaceuticals also provides regulatory services and laboratory testing to support pharmaceutical development. In recent major developments, Shukra Pharmaceuticals has expanded strategically by incorporating a new subsidiary, Shukra Healthtech Private Limited, focused on healthcare technology including manufacturing, trading, marketing, importing, exporting healthcare and wellness products, medical devices, and allied services. Shukra Pharmaceuticals holds an 85% stake in this subsidiary, signaling a strategic diversification into healthcare technology. Additionally, the company has entered a non-exclusive pan-India distribution agreement with Wockhardt Ltd. to distribute advanced anti-infective formulations and antibiotics across various institutional and government healthcare networks, enhancing its national presence and operational footprint. The company has also established new branch offices in major Indian cities such as Mumbai, Gurgaon, Bangalore, and Kolkata to support its expanding operations. Shukra Pharmaceuticals Limited operates primarily in the pharmaceutical industry with a focus on both domestic and international markets, serving pharmaceutical companies, healthcare institutions, and government healthcare facilities. The company’s main manufacturing facilities support large-scale production of injectable and oral solid dosage forms, complemented by its regulatory and laboratory services. It remains committed to quality standards with certifications like WHO, India CDSCO, and ISO 9000, solidifying its position as a growing player in the pharmaceutical sector leveraging innovation and expansion in both product lines and geographic reach.